Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX5290)

Drug Name
FF-10502-01 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMX5290

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting DNA synthesis (DNA synth)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nelarabine DMB6VEG leukaemia 2A60-2B33 Approved [2]
Glufosfamide DMEFCTP Pancreatic cancer 2C10 Phase 3 [1]
acelarin DMY96O3 Biliary tract cancer 2C17 Phase 3 [1]
TAR-200 DMSQZEP Bladder cancer 2C94 Phase 1 [1]
CLOTURIN DMKFMYR Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [3]
EPD-clofarabine DM149HL Solid tumour/cancer 2A00-2F9Z Terminated [4]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA synthesis (DNA synth) TTUBNVO NOUNIPROTAC Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Nelarabine. Drugs. 2008;68(4):439-47.
3 Inhibition of biosynthetic processes in P388 and Ehrlich ascites cells by cloturin. Drugs Exp Clin Res. 1988;14(9):575-80.
4 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.